BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Pharm Country

  FDA Authorizes COVID-19 Boosters for Kids 5-11 as Cases Creep Up

  COVID-19 would have claimed over 110,000 more lives in 2021 if vaccines weren’t available, according to a Pfizer-sponsored report on the first year of the U.S. vaccination program.

  May 17, 2022

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  On a Roll, CRISPR TX Taps Amgen Veteran P.K. Morrow as New CMO

  CRISPR Therapeutics tapped Amgen veteran Phuong Khanh (P.K.) Morrow, M.D., FACP, as its new chief medical officer.

  May 17, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Dark Horse Consulting Submits Guidance on Gene Therapy Safety

  Dark Horse Consulting Group (DHC), based in Walnut Creek, Calif., submitted proposed draft guidance to the FDA for gene therapy safety.

  May 17, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  With Promising Data, AVROBIO Plans Next Trial for Cystinosis Gene Therapy

  Avrobio presented clinical data on Tuesday at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) from its trial of AVR-RD-04, and preliminary results are promising.

  May 17, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  BioMidwest

  Deadly Venom is Being Turned into Life-Saving Medical Treatments

  Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.

  May 17, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Scholar Rock Slashes Headcount by 25% as it Advances SMA Therapeutic

  As Scholar Rock prepares to move forward with its experimental assets for spinal muscular atrophy, it has terminated 25% of its staff and also announced the loss of its chief medical officer.

  May 17, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Cytokinetics’ Heart Failure Drug Will Have its Day at the FDA

  Cytokinetics filed with the SEC reporting that the FDA planned to hold an advisory committee meeting to review its New Drug Application (NDA) for omecamtiv mecarbil.

  May 17, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  At Alto, New COO Mikael Eliasson Aims to Transform Psychiatry

  During the past several years, data generation, data mining and analytics have progressed to the point that it is now possible to bring precision medicine to psychiatry.

  May 17, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Drug Development

  Dyne, NeuBase, Graphite and More Present Programs at ASGCT

  The ASGCT’s 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.

  May 17, 2022

   · 

  4 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Idera Halts Enrollment For Melanoma Trial Following Positive Early Data

  Idera Pharmaceuticals has stopped patient enrollment early for its Phase II trial on a candidate melanoma drug after interim data delivered impressive results.

  May 17, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN